ArticleArchives of medical science : AMS2013
Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease.
Article in Archives of medical science : AMS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality.International journal of molecular sciences · 2024Article
- The Regulatory Variant -108C/T in the Promoter of Paraoxonase 1 (PON1) Gene has a More Important Role in Regulating PON1 Activity Compared to rs3735590 in 3'-UTR in Patients with Coronary Artery Disease.Advanced biomedical research · 2024Article
- Cardioprotective Role for Paraoxonase-1 in Chronic Kidney Disease.Biomedicines · 2022Article
- Paraoxonase 1 gene polymorphisms in lipid oxidation and atherosclerosis development.Frontiers in genetics · 2022Review
- The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases.International journal of molecular sciences · 2021Review
- Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery.Journal of clinical medicine · 2019Article
- Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance.Vascular health and risk management · 2018Review
- Dynamic changes of paraoxonase 1 activity towards paroxon and phenyl acetate during coronary artery surgery.BMC cardiovascular disorders · 2017Article
- Lipids, blood pressure and kidney update 2015.Lipids in health and disease · 2015Review
- Dialysis Modalities and HDL Composition and Function.Journal of the American Society of Nephrology : JASN · 2015Article
- Addressing the link between paraoxonase-1 gene variants and the incidence of early onset myocardial infarction.Archives of medical science : AMS · 2015Article
- Role of PON in anoxia-reoxygenation injury: a Drosophila melanogaster transgenic model.PloS one · 2014Article
- Aging affects high-density lipoprotein composition and function.Biochimica et biophysica acta · 2013Article
- Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis.Cholesterol · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSerum paraoxonase-1 (PON1) retards the oxidation of low-density lipoprotein and cell membranes and is atheroprotective. Polymorphisms in the promoter region of the PON1 gene have been shown to affect serum PON1 levels and have been related to the presence of coronary heart disease (CHD) in some studies. However, contradictory results have been reported with regard to promoter region polymorphisms and CHD presence; therefore we have re-examined the effects of the C-108T and G-909C promoter polymorphisms on PON1 levels and the presence of CHD in a large case-control study. MATERIAL AND
methodsParaoxonase-1 activity, concentration and the C-108T and G-909C polymorphisms were measured in 417 people with CHD and 282 healthy controls, in a case control study.
resultsParaoxonase-1 activity and concentration were significantly lower in the CHD population compared to controls regardless of their C-108T and G-909C genotype (p < 0.001). Paraoxonase-1 activity was significantly different in the C-108T genotypes in both the control and CHD groups in the order TT < TC < CC (p < 0.01). Paraoxonase-1 concentration was significantly different in the CHD group only in the G-909C genotype in the order GG > GC > CC (p < 0.01). Haplotype analysis revealed no consistent patterns of PON1 activity in the CHD population; however, in the controls PON1 activity differed between haplotypes GGCC > GGTC > GGTT (p < 0.05) and GCCC > GCTC > GCTT (p < 0.02). Neither promoter polymorphism was associated with CHD presence.
conclusionsParaoxonase-1 status was significantly lower in people with CHD and was affected by the promoter region polymorphisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.